Thyrocare Technologies Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Thyrocare Technologies Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Self-Funding Ratio: Over the last 3 years its own operating cash covered its investment spending (capex) 4.8 times. Higher than 90% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹172Over the last 3 years, every ₹100 of reported profit came with ₹172 of operating cash.
Higher than 79% of Healthcare companies in India.
Self-Funding Ratio
4.8×Over the last 3 years its own operating cash covered its investment spending (capex) 4.8 times.
Higher than 90% of Healthcare companies in India.
Cash Locked Ratio
₹6For every ₹100 of sales, ₹6 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹15 tied up three years earlier.
Less money tied up than 77% of Healthcare companies in India.
Growth quality
Steadiness Ratio
3/3 · 3/3Sales and profit both grew in each of the last 3 years.
Steadier than 83% of Healthcare companies in India.
Growth Efficiency Ratio
₹32Sales grew 59% in 3 years; of every extra ₹100 of sales, ₹32 became extra profit.
Higher than 80% of Healthcare companies in India.
Asset Productivity Ratio
+59% / +18%In 3 years sales changed by +59% while total assets changed by +18%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
18.5×Debt due within a year is covered 18.5 times by its yearly operating cash.
Higher than 82% of Healthcare companies in India.
Cash Cushion Ratio
+2%Cash, after subtracting all debt, equals 2% of its market value (net cash).
Higher than 72% of Healthcare companies in India.
Tangible Assets Ratio
85%Of every ₹100 the company owns, ₹85 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 77% of Healthcare companies in India.
Tangible Net Worth Ratio
81%Of every ₹100 of net worth, ₹81 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 72% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Thyrocare Technologies Limited owes ₹0.22 for every ₹1 it owns. Net profit rose 78% in the year to Mar 2026, and grew 36% a year on average over 3 years.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
42.8Investors pay ₹42.8 for every ₹1 of Thyrocare Technologies Limited's yearly profit, higher than 61% of Healthcare companies in India.
P/B ratio
12.83The share price is 12.83 times Thyrocare Technologies Limited's book value per share, higher than 91% of Healthcare companies in India.
Market cap
₹7,514 CrThe total market value of all of Thyrocare Technologies Limited's shares at today's price (share price × number of shares), larger than 57% of Healthcare companies in India. PosiCap size class: Mini Cap.
Net worth (book value)
₹586 CrWhat Thyrocare Technologies Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹36.79Net worth divided by the number of shares. The share price of ₹472.10 is 12.8 times this, which is the P/B above.
Return on equity (ROE)
30.0%Thyrocare Technologies Limited earned 30.0% on its shareholders' money over the last year, higher than 93% of Healthcare companies in India.
Owes vs Owns
0.22×Thyrocare Technologies Limited owes ₹0.22 for every ₹1 it owns (low), lower than 80% of Healthcare companies in India.
Dividend yield
1.87%Thyrocare Technologies Limited pays 1.87% of its share price as dividends a year, higher than 90% of dividend-paying Healthcare companies in India.
Revenue growth
+21%Revenue rose 21% in the year to Mar 2026, and grew 17% a year on average over 3 years.
Profit growth
+78%Net profit rose 78% in the year to Mar 2026, and grew 36% a year on average over 3 years.
Profit margin
19.8%Thyrocare Technologies Limited keeps ₹20 of every ₹100 of revenue as net profit.
Cash quality
1.3×Cash from Thyrocare Technologies Limited's business was 1.3× its reported profit in the year to Mar 2026 — its profit turned into cash.
Interest cover
73.1×Thyrocare Technologies Limited's operating profit covered its interest costs 73.1 times in the year to Mar 2026.
Cash vs debt
Net cashThyrocare Technologies Limited held ₹180 Cr more cash than debt (net cash) at Mar 2026.
Questions
What is Thyrocare Technologies Limited's P/E ratio?
Investors pay ₹42.8 for every ₹1 of Thyrocare Technologies Limited's yearly profit, higher than 61% of Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Thyrocare Technologies Limited: ₹7,514 Cr ÷ ₹586 Cr (31 Mar 2026) = 12.8.
What is Thyrocare Technologies Limited's return on equity?
Thyrocare Technologies Limited earned 30.0% on its shareholders' money over the last year, higher than 93% of Healthcare companies in India.
How much does Thyrocare Technologies Limited owe compared with what it owns?
Thyrocare Technologies Limited owes ₹0.22 for every ₹1 it owns (low), lower than 80% of Healthcare companies in India.
Does Thyrocare Technologies Limited pay a dividend?
Yes. Thyrocare Technologies Limited pays 1.87% of its share price as dividends a year, higher than 90% of dividend-paying Healthcare companies in India.
Is Thyrocare Technologies Limited's revenue growing?
Revenue rose 21% in the year to Mar 2026, and grew 17% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.